Multiple Myeloma Clinical Trials in Seattle, Washington

13 studies are recruiting for multiple myeloma in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Collection of Tissue Samples for Cancer Research

   Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research …

   Stage

   Not phased

   Ages

   0 and older

   Site

   Fred Hutchinson, Seattle, Washington

   Locations

   17 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00900198 on ClinicalTrials.gov

2. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

3. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Swedish Cancer Institute, Seattle, Washington

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

4. A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

   The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste ch…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   38 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06500884 on ClinicalTrials.gov

5. Selinexor and Backbone Treatments of Multiple Myeloma Patients

   This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to b…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutch Cancer Center, Seattle, Washington

   Locations

   25 in total

   Run by

   Karyopharm Therapeutics Inc

   See if you can join NCT02343042 on ClinicalTrials.gov

6. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

   Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center. /ID# 267940, Seattle, Washington

   Locations

   46 in total

   Run by

   AbbVie

   See if you can join NCT05650632 on ClinicalTrials.gov

7. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

   This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that r…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   VA Puget Sound Health Care System, Seattle, Washington

   Locations

   42 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT05137054 on ClinicalTrials.gov

8. Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

   This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patien…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   10 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT05231629 on ClinicalTrials.gov

9. Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adul…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Swedish Medical Center - Seattle /ID# 268052, Seattle, Washington

   Locations

   27 in total

   Run by

   AbbVie

   See if you can join NCT06896916 on ClinicalTrials.gov

10. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

    The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Swedish Cancer Institute, Seattle, Washington

    Locations

    40 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT03761108 on ClinicalTrials.gov

11. PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma

    This study will evaluate the feasibility of a digital health coaching program for adults with relapsed or refractory multiple myeloma (R/R MM). One hundred adults with R/R MM will be enrolled at The University of Washington. Individuals who agree to take part in the study and sign an informed conse…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Washington, Seattle, Washington

    Run by

    Pack Health

    See if you can join NCT05956457 on ClinicalTrials.gov

12. Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

    This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Washington, Seattle, Washington

    Locations

    2 in total

    Run by

    Pack Health

    See if you can join NCT05053607 on ClinicalTrials.gov

13. Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

    All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achie…

    Stage

    Not phased

    Ages

    18 and older

    Site

    All4Cure, Seattle, Washington

    Run by

    All4Cure

    See if you can join NCT06149910 on ClinicalTrials.gov